WO2006073496A3 - Procedes de vaccination a base d'aav recombine - Google Patents

Procedes de vaccination a base d'aav recombine Download PDF

Info

Publication number
WO2006073496A3
WO2006073496A3 PCT/US2005/027091 US2005027091W WO2006073496A3 WO 2006073496 A3 WO2006073496 A3 WO 2006073496A3 US 2005027091 W US2005027091 W US 2005027091W WO 2006073496 A3 WO2006073496 A3 WO 2006073496A3
Authority
WO
WIPO (PCT)
Prior art keywords
pathogen
methods
vector
eliciting
immune response
Prior art date
Application number
PCT/US2005/027091
Other languages
English (en)
Other versions
WO2006073496A2 (fr
Inventor
Richard Peluso
Susan Arnold
Jason Wustner
Philip R Johnson
Alan M Schultz
Anthony M Stepan
Original Assignee
Targeted Genetics Corp
Childrens Hospital Inc
Richard Peluso
Susan Arnold
Jason Wustner
Philip R Johnson
Alan M Schultz
Anthony M Stepan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Targeted Genetics Corp, Childrens Hospital Inc, Richard Peluso, Susan Arnold, Jason Wustner, Philip R Johnson, Alan M Schultz, Anthony M Stepan filed Critical Targeted Genetics Corp
Priority to EP05856895A priority Critical patent/EP1771571A2/fr
Publication of WO2006073496A2 publication Critical patent/WO2006073496A2/fr
Publication of WO2006073496A3 publication Critical patent/WO2006073496A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne des matières à base de virus adéno-associé recombiné (rAAV) et des procédés visant à déclencher une réaction immunitaire à l'égard d'un organisme pathogène. L'invention concerne des ensembles de vecteurs comprenant un vecteur initial et un vecteur de rappel, au moins un des vecteurs dudit ensemble étant un vecteur rAAV; des procédés visant à déclencher une réaction immunitaire prophylactique chez un sujet mammifère susceptible d'être infecté par un organisme pathogène tel que, par exemple, un virus à ARN, y compris le VIH-1; et des procédés visant à déclencher une réaction immunitaire thérapeutique chez un sujet mammifère infecté par un organisme pathogène et ayant atteint un état pathologique associé audit pathogène, tel que, par exemple, un virus à ARN, y compris le VIH-1. L'invention concerne en particulier des procédés visant à déclencher une réaction immunitaire de rappel renforcée chez un sujet mammifère susceptible d'être infecté ou ayant été infecté par un organisme pathogène.
PCT/US2005/027091 2004-07-30 2005-07-29 Procedes de vaccination a base d'aav recombine WO2006073496A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP05856895A EP1771571A2 (fr) 2004-07-30 2005-07-29 Procedes de vaccination a base d'aav recombine

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59288904P 2004-07-30 2004-07-30
US60/592,889 2004-07-30

Publications (2)

Publication Number Publication Date
WO2006073496A2 WO2006073496A2 (fr) 2006-07-13
WO2006073496A3 true WO2006073496A3 (fr) 2007-05-03

Family

ID=36647930

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/027091 WO2006073496A2 (fr) 2004-07-30 2005-07-29 Procedes de vaccination a base d'aav recombine

Country Status (2)

Country Link
EP (1) EP1771571A2 (fr)
WO (1) WO2006073496A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0800485B8 (pt) * 2008-01-17 2021-05-25 Univ Minas Gerais vetores virais recombinantes, composição vacinal para leishmaniose e método de vacinação para leishmaniose
WO2012142526A1 (fr) 2011-04-14 2012-10-18 Modiano Jaime Utilisation de l'expression tumorale de fas pour déterminer la réponse à une thérapie anticancéreuse
EP3491008A2 (fr) 2016-07-26 2019-06-05 BioMarin Pharmaceutical Inc. Nouvelles protéines de capside de virus adéno-associés
EP3790627A2 (fr) 2018-05-09 2021-03-17 BioMarin Pharmaceutical Inc. Méthodes de traitement de la grippe
TW202005978A (zh) 2018-05-14 2020-02-01 美商拜奧馬林製藥公司 新穎肝靶向腺相關病毒載體
CN110857440B (zh) 2018-08-23 2021-02-19 武汉纽福斯生物科技有限公司 重组人ⅱ型线粒体动力蛋白样gtp酶基因序列及其应用
TW202039856A (zh) * 2019-03-28 2020-11-01 西班牙商艾斯提夫製藥股份有限公司 製造重組病毒載體之方法
AR118928A1 (es) * 2019-05-14 2021-11-10 Biomarin Pharm Inc Métodos de redosificación de vectores de terapia génica
EP4388107A1 (fr) * 2021-08-20 2024-06-26 Massachusetts Eye & Ear Infirmary Nouvelles méthodes d'utilisation du virus adéno-associé 11 (aav11)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999043843A1 (fr) * 1998-02-27 1999-09-02 Johns Hopkins University School Of Medicine Produits carbonises a activite catalytique reduite
WO2001068888A2 (fr) * 2000-03-14 2001-09-20 Neurologix, Inc. Production de vecteurs de capsides chimeres
WO2003042397A2 (fr) * 2001-11-13 2003-05-22 The Trustees Of The University Of Pennsylvania Methode de detection et/ou d'identification de sequences de virus associes aux adenovirus (aav) et d'isolation de nouvelles sequences ainsi identifiees
WO2006078279A2 (fr) * 2004-04-28 2006-07-27 The Trustees Of The University Of Pennsylvania Liberation sequentielle de molecules immunogenes par administrations mediees par un adenovirus ou un virus adenoassocie

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999043843A1 (fr) * 1998-02-27 1999-09-02 Johns Hopkins University School Of Medicine Produits carbonises a activite catalytique reduite
WO2001068888A2 (fr) * 2000-03-14 2001-09-20 Neurologix, Inc. Production de vecteurs de capsides chimeres
WO2003042397A2 (fr) * 2001-11-13 2003-05-22 The Trustees Of The University Of Pennsylvania Methode de detection et/ou d'identification de sequences de virus associes aux adenovirus (aav) et d'isolation de nouvelles sequences ainsi identifiees
WO2006078279A2 (fr) * 2004-04-28 2006-07-27 The Trustees Of The University Of Pennsylvania Liberation sequentielle de molecules immunogenes par administrations mediees par un adenovirus ou un virus adenoassocie

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
CLARK K REED ET AL: "A single dose, adeno-associated virus vector SIV vaccine elicits long-lived immune responses in macaques", JOURNAL OF MEDICAL PRIMATOLOGY, vol. 29, no. 3-4, August 2000 (2000-08-01), & 17TH ANNUAL SYMPOSIUM ON NONHUMAN PRIMATE MODELS FOR AIDS; NEW ORLEANS, LOUISIANA, USA; OCTOBER 06-09, 1999, pages 290 - 291, XP009071318, ISSN: 0047-2565 *
DORONIN K ET AL: "Tumor-specific, replication-competent adenovirus vectors overexpressing the adenovirus death protein", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 74, no. 13, July 2000 (2000-07-01), pages 6147 - 6155, XP002162706, ISSN: 0022-538X *
DORONIN KONSTANTIN ET AL: "Overexpression of the ADP (E3-11.6K) protein increases cell lysis and spread of adenovirus.", VIROLOGY, vol. 305, no. 2, 20 January 2003 (2003-01-20), pages 378 - 387, XP002414301, ISSN: 0042-6822 *
GALLEZ-HAWKINS G ET AL: "DNA and low titer, helper-free, recombinant AAV prime-boost vaccination for cytomegalovirus induces an immune response to CMV-pp65 and CMV-IE1 in transgenic HLA A*0201 mice", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 23, no. 6, 21 December 2004 (2004-12-21), pages 819 - 826, XP004637089, ISSN: 0264-410X *
HALBERT C L ET AL: "Repeat transduction in the mouse lung by using adeno-associated virus vectors with different serotypes", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 74, no. 3, February 2000 (2000-02-01), pages 1524 - 1532, XP002242061, ISSN: 0022-538X *
JOHNSON PHILIP R ET AL: "Novel adeno-associated virus vector vaccine restricts replication of simian immunodeficiency virus in macaques", JOURNAL OF VIROLOGY, vol. 79, no. 2, January 2005 (2005-01-01), pages 955 - 965, XP002395741, ISSN: 0022-538X *
JOHNSON PHILIP R ET AL: "Pre-clinical evaluation of a novel HIV vaccine based on an adeno-associated virus vector.", PEDIATRIC RESEARCH, vol. 53, no. 4 Part 2, April 2003 (2003-04-01), & ANNUAL MEETING OF THE PEDIATRIC ACADEMIC SOCIETIES'; SEATTLE, WA, USA; MAY 03-06, 2003, pages 334A, XP009071316, ISSN: 0031-3998 *
LICHTENSTEIN D L ET AL: "FUNCTIONS AND MECHANISMS OF ACTION OF THE ADENOVIRUS E3 PROTEINS", INTERNATIONAL REVIEWS OF IMMUNOLOGY, HARWOOD ACADEMIC PUBLISHERS, US, vol. 23, no. 1/2, January 2004 (2004-01-01), pages 75 - 111, XP009071853, ISSN: 0883-0185 *
NEWMAN M J: "HETEROLOGOUS PRIME-BOOST VACCINATION STRATEGIES FOR HIV-1: AUGMENTING CELLULAR IMMUNE RESPONSES", CURRENT OPINION IN INVESTIGATIONAL DRUGS, PHARMAPRESS, US, vol. 3, no. 3, March 2002 (2002-03-01), pages 374 - 378, XP009037697, ISSN: 1472-4472 *
PEDEN CARMEN S ET AL: "Circulating anti-wild-type adeno-associated virus type 2 (AAV2) antibodies inhibit recombinant AAV2 (rAAV2)-mediated, but not rAAV5-mediated, gene transfer in the brain", JOURNAL OF VIROLOGY, vol. 78, no. 12, June 2004 (2004-06-01), pages 6344 - 6359, XP002395740, ISSN: 0022-538X *
RAMA RAO AMARA ET AL: "CONTROL OF A MUCOSAL CHALLENGE AND PREVENTION OF AIDS BY A MULTIPROTEIN DNA/MVA VACCINE", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 292, no. 5514, 6 April 2001 (2001-04-06), pages 69 - 74, XP000986110, ISSN: 0036-8075 *
SHIVER J W ET AL: "RECENT ADVANCES IN THE DEVELOPMENT OF HIV-1 VACCINES USING REPLICATION-INCOMPETENT ADENOVIRUS VECTORS", ANNUAL REVIEW OF MEDICINE : SELECTED TOPICS IN THE CLINICAL SCIENCES, ANNUAL REVIEWS INC., PALO ALTO, CA, US, vol. 55, 10 December 2003 (2003-12-10), pages 355 - 372, XP009058216, ISSN: 0066-4219 *
TOLLEFSON ANN E ET AL: "The Ed3-11.6-kDa adenovirus death protein (ADP) is required for efficient cell death: Characterization of cells infected with adp mutants", VIROLOGY, ACADEMIC PRESS,ORLANDO, US, vol. 220, no. 1, 1996, pages 152 - 162, XP002162708, ISSN: 0042-6822 *
XIN KE-QIN ET AL: "A novel recombinant adeno-associated virus vaccine induces a long-term humoral immune response to human immunodeficiency virus", HUMAN GENE THERAPY, vol. 12, no. 9, 10 June 2001 (2001-06-10), pages 1047 - 1061, XP002395739, ISSN: 1043-0342 *

Also Published As

Publication number Publication date
EP1771571A2 (fr) 2007-04-11
WO2006073496A2 (fr) 2006-07-13

Similar Documents

Publication Publication Date Title
WO2006073496A3 (fr) Procedes de vaccination a base d'aav recombine
WO2019060454A3 (fr) Virus adéno-associé à variant de capsides et leurs procédés d'utilisation
WO2020060403A3 (fr) Vaccin contre le virus de la peste porcine africaine
EP4272728A3 (fr) Capsides variantes de virus adéno-associés et leur utilisation pour inhiber l'angiogenèse
WO2017197355A3 (fr) Variantes de capsides de virus adéno-associé et leurs procédés d'utilisation
WO2006020071A3 (fr) Constructions vaccinales et combinaisons de vaccins conçues pour ameliorer l'etendue de la reaction immunitaire a diverses souches et variantes du vih
WO2008026225A3 (fr) Vaccin contre l'infection par le virus chikungunya
WO2006063101A3 (fr) Vaccins favorisant la reponse rapide contre la grippe aviaire pandemique
EP1200109A4 (fr) Induction de reponses immunitaires cellulaires au virus de l'hepatite c mettant en oeuvre des compositions de peptides et d'acide nucleique
EP3266464A3 (fr) Thérapeutique à base de levure pour infection chronique par l'hépatite b
JP2012503011A5 (ja) 慢性ｃ型肝炎ウイルス感染症のための酵母系免疫治療組成物
JP2015501840A5 (fr)
WO2007095320A3 (fr) Antigènes du papillomavirus humain, compositions de vaccin et méthodes
WO2007008918A3 (fr) Vaccins de virus comprenant des proteines immunomodulatrices reliees a une enveloppe, et methode d'utilisation associee
WO2008115199A3 (fr) Vaccins viraux chimériques
WO2001089559A3 (fr) Vaccin a poxvirus recombinant contre le virus du syndrome disgenesique respiratoire porcin (vsdrp)
WO2006073431A3 (fr) Genes du virus de la fievre aphteuse exprimant des recombines avipox
WO2001042445A3 (fr) Utilisation de virus de parainfluenza (piv) de recombinaison comme vecteurs aux fins de protection contre des maladies et infections provoquees par un piv ou par d'autres pathogenes humains
WO2004085633A8 (fr) Nouveau virus humain provoquant le syndrome respiratoire aigu severe (sars) et son utilisation
WO2009080715A3 (fr) Vaccins anti-malaria
WO2007046839A3 (fr) Nouveaux vaccins a base de virus vivant
WO2006024240A3 (fr) Composition vaccinale contre le virus de l'hepatite c
WO2009074861A3 (fr) Vaccin amélioré
GB2429711A (en) Heart and skeletal muscle inflammation (HSMI) virus
NZ601980A (en) Recombinant proteins for use in vaccine, antibodies against said proteins, and diagnostic and therapeutic methods including the same

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2005856895

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2005856895

Country of ref document: EP